Developer docs
API playgroundTry for free, no card

Search company profiles

PRGS&Tech

Full company profile

uuid0026oc9

Namestring
PRGS&Tech
Websiteurl
prgst.com
Company typeenum
Private
Founded yearint
2017
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBusan, South Korea
HQ citystring
Busan
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, drug development, biopharmaceutical research, treatment development, medical research
Industry1 code
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Misc Health & Allied Services, Nec8090
Product category
Rare Disease Therapeutics R&D
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PRGS&Tech is a research and development center that develops treatments for rare diseases. The company is engaged in therapeutic R&D activities to address unmet medical needs in the rare disease space, operating as a privately held entity based in Busan, South Korea.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Rare disease therapeutics R&D
CategoryRare Disease Therapeutics
Description

Research and development services focused on discovering and developing therapeutic treatments for rare diseases, targeted at pharmaceutical/biotech partners for licensing or co-development.

No data
Peers10 records
TypeDirect peer
Description

US-based rare disease-focused drug developer with a multi-asset pipeline; directly comparable strategic model (small focused teams pursuing rare disease therapeutics), though at much larger scale.

TypeBroad incumbent
Description

Established Korean pharmaceutical company with rare disease and specialty pipeline programs; provides a comparable larger incumbent view on the Korean rare disease drug development landscape.

TypeBroad incumbent
Description

Korean pharmaceutical company with rare disease and specialty therapeutics programs; a relevant Korean incumbent comparable in therapeutic orientation.

TypeEmerging player
Description

Clinical-stage gene editing company with rare disease programs (e.g., hemoglobinopathies); overlapping modality and rare-disease focus, though at significantly more advanced and well-capitalized stage.

TypeEmerging player
Description

Clinical-stage gene therapy company focused exclusively on rare monogenic CNS diseases; similar early-to-mid stage profile targeting rare disease indications.

TypeDirect peer
Description

Biotechnology company developing antibody therapeutics, including for rare diseases, with a focused R&D-centric operating model comparable to PRGS&Tech's lean structure.

TypeDirect peer
Description

Korean clinical-stage biotech developing therapeutics including in rare and serious disease indications, with comparable company size and Korean R&D base to PRGS&Tech.

TypeDirect peer
Description

Pure-play rare disease biotechnology company developing and commercializing therapeutics for rare and ultra-rare genetic diseases; directly comparable therapeutic focus.

9SK Biopharmaceuticals
TypeBroad incumbent
Description

Korea-based biopharmaceutical company operating in CNS and rare/specialty disease drug development; substantially larger and more advanced, but operating in the same Korean biotech ecosystem and rare-disease orientation.

TypeBroad incumbent
Description

Global biotechnology company dedicated to rare disease therapeutics across multiple indications; comparable strategic positioning around rare disease specialty markets.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PRGS&Tech

Rare Disease Therapeutics R&Dprgst.com

PRGS&Tech firmographics

Firmographics
Name
PRGS&Tech
Website
https://prgst.com
Company type
Private
Founded year
2017
Headcount range
1–10 employees
Ownership category
akta.pro rank

PRGS&Tech industry classification

Industry
Product category
Rare Disease Therapeutics R&D
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Drug development
  • Biopharmaceutical research
  • Treatment development
  • Medical research

Where PRGS&Tech is headquartered

Location

Headquarters

HQ city
Busan
HQ country
South Korea
HQ region
Asia

Markets served

PRGS&Tech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

PRGS&Tech product offering

Product offering

Core offering

PRGS&Tech is a research and development center that develops treatments for rare diseases. The company is engaged in therapeutic R&D activities to address unmet medical needs in the rare disease space, operating as a privately held entity based in Busan, South Korea.

Differentiator

Problem solved

Functional benefit

Products and services

  • Rare disease therapeutics R&D Research and development services focused on discovering and developing therapeutic treatments for rare diseases, targeted at pharmaceutical/biotech partners for licensing or co-development.

Companies that use PRGS&Tech

Customer profile

Ideal customer profiles1 record

PRGS&Tech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

PRGS&Tech competitors and assessment

Company assessment

Direct peers

  • BridgeBio Pharma: US-based rare disease-focused drug developer with a multi-asset pipeline; directly comparable strategic model (small focused teams pursuing rare disease therapeutics), though at much larger scale.
  • AbCellera Biologics: Biotechnology company developing antibody therapeutics, including for rare diseases, with a focused R&D-centric operating model comparable to PRGS&Tech's lean structure.
  • LegoChem Biosciences: Korean clinical-stage biotech developing therapeutics including in rare and serious disease indications, with comparable company size and Korean R&D base to PRGS&Tech.
  • Ultragenyx Pharmaceutical: Pure-play rare disease biotechnology company developing and commercializing therapeutics for rare and ultra-rare genetic diseases; directly comparable therapeutic focus.

Broad incumbents

  • Hanmi Pharmaceutical: Established Korean pharmaceutical company with rare disease and specialty pipeline programs; provides a comparable larger incumbent view on the Korean rare disease drug development landscape.
  • Yuhan Corporation: Korean pharmaceutical company with rare disease and specialty therapeutics programs; a relevant Korean incumbent comparable in therapeutic orientation.
  • SK Biopharmaceuticals: Korea-based biopharmaceutical company operating in CNS and rare/specialty disease drug development; substantially larger and more advanced, but operating in the same Korean biotech ecosystem and rare-disease orientation.
  • BioMarin Pharmaceutical: Global biotechnology company dedicated to rare disease therapeutics across multiple indications; comparable strategic positioning around rare disease specialty markets.

Emerging players

  • CRISPR Therapeutics: Clinical-stage gene editing company with rare disease programs (e.g., hemoglobinopathies); overlapping modality and rare-disease focus, though at significantly more advanced and well-capitalized stage.
  • Taysha Gene Therapies: Clinical-stage gene therapy company focused exclusively on rare monogenic CNS diseases; similar early-to-mid stage profile targeting rare disease indications.

Market position

Customer concentration

PRGS&Tech social profiles

Digital presence

PRGS&Tech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PRGS&Tech leadership team

Management profile

Number of profiles

PRGS&Tech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PRGS&Tech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PRGS&Tech

What does PRGS&Tech do?

PRGS&Tech is a research and development center that develops treatments for rare diseases. The company is engaged in therapeutic R&D activities to address unmet medical needs in the rare disease space, operating as a privately held entity based in Busan, South Korea.

When was PRGS&Tech founded?

PRGS&Tech was founded in 2017. It employs 1 to 10 people.

Where is PRGS&Tech based?

PRGS&Tech is headquartered in Busan, South Korea, in the Asia region.

Who are PRGS&Tech's main competitors?

Direct peers on record are BridgeBio Pharma, AbCellera Biologics, LegoChem Biosciences and Ultragenyx Pharmaceutical. Broad incumbents are Hanmi Pharmaceutical, Yuhan Corporation, SK Biopharmaceuticals and BioMarin Pharmaceutical. Emerging players are CRISPR Therapeutics and Taysha Gene Therapies.

Does PRGS&Tech have an API?

No public API is recorded for PRGS&Tech.

What industry is PRGS&Tech in?

PRGS&Tech's product category is Rare Disease Therapeutics R&D. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 54171 and its SIC code is 8090.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals